Other · developed by Equillium
EQ101 is a drug studied in alopecia areata, including alopecia totalis and alopecia universalis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05589610 | Phase 2 | Alopecia Areata | Completed | EQ |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AlopeciaAlopecia AreataAlopecia TotalisAlopecia Universalis
Updated Nov 15, 2026. Something wrong or missing? Report it on the EQ page.
See EQ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
EQ catalysts and pipeline →